• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » ConforMIS looks to get back on line this month, affirms guidance

ConforMIS looks to get back on line this month, affirms guidance

October 6, 2015 By Brad Perriello

ConforMISConforMIS (NSDQ:CFMS) said today that it expects to get its customized knee implants back on line this month, after an independent investigation of the problem behind the recall of some 950 of its customized knee implants found no further cause for concern.

Last August Bedford, Mass.-based ConforMIS said it had received 3 complaints of moisture on the patient-specific instrumentation used with the implants, although all 3 procedures went off without a hitch. The recall affected its iUni, iDuo, iTotal CR and iTotal PS devices made at a new plant in nearby Wilmington, Mass., between July 18 and August 28. The news prompted ConforMIS to pare its outlook for the rest of the year, leading investors to push CFMS share prices down 19%.

Today ConforMIS said an independent testing laboratory found that the moisture was ethylene glycol residue that “posed no significant health hazard to patients.” No residue was found on any of the implants tested by the lab, the company said.

“Based on the results of the investigation, ConforMIS believes that no monitoring of patients is necessary,” according to a press release. “The results of ConforMIS’ investigation suggest that the affected instrumentation underwent the commonly used ethylene oxide sterilization process in the presence of excess water and, as a result, contained small amounts of ethylene glycol residue. ConforMIS is in the process of completing final testing and implementing corrective actions, and expects to resume full production in October.”

ConforMIS affirmed the reduced guidance for fiscal 2015 it issued August 31, saying it still expects revenues of $64 million to $66 million, down from $72 million to $74 million. The company is slated to release its fiscal 3rd-quarter results Nov. 2.

CFMS shares lost -19.1% August 31, falling to $16 apiece, but closed yesterday at $18.90 each, off -4.4% since the recall news. The shares opened today at $18.76 each and were up 1.3% on the day to $19.17 shortly after the bell.

Filed Under: Orthopedics, Recalls, Regulatory/Compliance Tagged With: conformis

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy